| 螺内酯对老年人重度心力衰竭的疗效观察 |
| |
| 引用本文： | 韩兰唐,王立新,高云英,李瑞玲,狄巨岚.螺内酯对老年人重度心力衰竭的疗效观察[J].河北北方学院学报(医学版),2002,19(6):18-20. |
| |
| 作者姓名： | 韩兰唐 王立新 高云英 李瑞玲 狄巨岚 |
| |
| 作者单位： | 1. 张家口医学一附院老年心内科,075000
2. 张家口市第三人民医院,075000 |
| |
| 摘 要： | 目的 :探讨小剂量醛固酮拮抗剂螺内酯治疗老年人重度慢性充血性心力衰竭 (CHF)疗效和安全性。方法 :采用多中心、随机、单盲、安慰剂对照、平行组试验。入选老年重度CHF患者 15 2例 ,随机分为螺内酯组 (A组 )和对照组 (B组 ) ,均予标准三联抗心衰治疗 ,A组联用螺内酯 (2 0～ 4 0mg/d) ,B组联用与螺内酯外观相同的淀粉安慰剂。治疗前和治疗后 2周、4周、8周分别进行心功能 (NYHA)分级评估 ,心电图、超声心动图、血常规、生化等检查 ,并进行对照。结果 :治疗 8周后A、B两组心功能分级、无创心排量指标均显著改善 (P <0 .0 5 ) ;与B组比较 ,A组改善更显著 (P <0 .0 5 )。无肝、肾功能损害及血脂、血糖升高 ,未见高血钾症 ,毒副作用少。结论 :应用螺内酯治疗老年人重度CHF疗效肯定、可靠、安全性好、值得推广。
|
| 关 键 词： | 心力衰竭 充血性 老年人 醛固酮拮抗剂 螺内酯 |
| 文章编号： | 1005-8796(2002)06-18-03 |
Efficacy and Safety of Spironolactone in Treating Aged Patients with Congestive Heart Failure |
| |
| Han Lantang,Wang Lixin,Gao Yunying et al The First Affiliated Hospital of Zhangjiakou Medical College,Zhangjiakou,China.Efficacy and Safety of Spironolactone in Treating Aged Patients with Congestive Heart Failure[J].Journal of Hebei North University:Medical Edition,2002,19(6):18-20. |
| |
| Authors: | Han Lantang Wang Lixin Gao Yunying The First Affiliated Hospital of Zhangjiakou Medical College Zhangjiakou China |
| |
| Institution: | Han Lantang,Wang Lixin,Gao Yunying et al The First Affiliated Hospital of Zhangjiakou Medical College,Zhangjiakou,075000,China |
| |
| Abstract: | Objective: To study the clinical therapeutic efficacy and safety of spironolactone in treating aged patients with chronic congestive heart failure(CHF). Methods: The multicentre, random, single-blind, placebo-controlled, parallel group trial were conducted in 2 hospitals. 152 aged patients with CHF(NYHA class IV) were divided into two group A and B atrandom.The patients in two groups all received standard treatment(ACE-I, diurectics and digitalis). In addition, patients in group A were given spironolactone(20-40mg/d), patients in group B were given placebo. The heart function (by NYHA), electrocardiogram, echocardiography, blood routine and biochemistry were checked before and during the treatment for 2 weeks, 4 weeks and 8 weeks. Result: Eight weeks after treatment, NYHA class , LVEF, SV, CO and CI were improved significantly in both groups (P<0.05), which were more significant in group A than those in group B (P<0.05). Nobody got hyperpotassemia. The side effects were not popular. Conclusion: Use of spironolactone is absolutely reliable and safe for aged patients with CHF and worth of popularizing. |
| |
| Keywords: | Heart failure congestive Aged Aldosterone antagonist Spironolactone |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
